Page 32 - Brian Ritchie News Today

Managing editor WEIRTON — The City of Weirton is remaining an invested member of the Business Development Corp. of the Northern Panhandle following Monday’s city council meeting. Council voted unanimously, Monday, on a resolution to authorize financial support in the amount of $33,062.50 to the BDC, which is involved in economic development activities in Hancock and Brooke counties. The resolution originally was presented to council in January but was tabled to allow for further discussi...

Managing editor MEMORIAL — Area emergency responders, family and friends gathered in Weirton’s Municipal Plaza Wednesday night for a candlelight memorial in tribute to the life of Brian Ritchie, a lieutenant with the Weirton Fire Department and assistant chief with the Hooverson Heights Volunteer Fire Department, who died Tuesday following a battle with COVID-19. -- Craig Howell WEIRTON – Firefighters from up and down the Ohio Valley, along with police officers and other emergency respond...

Staff writer MEMORIAL — Area emergency responders, family and friends gathered in Weirton’s Municipal Plaza Wednesday night for a candlelight memorial in tribute to the life of Brian Ritchie, a lieutenant with the Weirton Fire Department and assistant chief with the Hooverson Heights Volunteer Fire Department, who died Tuesday following a battle with COVID-19. -- Craig Howell WEIRTON — Firefighters from up and down the Ohio Valley, along with police officers and other emergency resp...

Onxeo Enters Clinical Research Agreement with Institut Curie to Conduct a Phase 1b/2 Clinical Trial of AsiDNA in Combination With Radiotherapy For Treatment of High-Grade Glioma Relapse in Children 1 Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, today announces that the Company has entered into a clinical research agreement with Inst...

PARIS--(BUSINESS WIRE)--Regulatory News:Onxeo S.A. (Euronext Growth: ALONX; Nasdaq First North: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, today provides a business upda...

Staff writer NEW ADDITION — Tim Buchmelter of Hooverson Heights stood before an automated contactless fever-detecting camera before entering the Brooke County Courthouse on Tuesday. The device has been added to deter the spread of COVID-19. WELLSBURG — On Tuesday the Brooke County Commission learned of efforts to aid three local firefighters and noted they have installed a new tool aimed at deterring spread of the coronavirus. Christina White, director of the county’s 911 center, annou...

Onxeo S.A.: Onxeo Publishes Letter to Shareholders and Provides Update on Its Developments Regulatory News: Onxeo S.A. (Euronext Growth: ALONX; Nasdaq First North: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, today provides a business update at the occasion of the publication of its Letter to Shareholders available on this link "Despite the pandemic ...

Published: Feb 01, 2021 FINTEPLA offers a new treatment option for patients in Germany with Dravet syndrome, a rare, devastating, infant-onset epilepsy marked by frequent seizures, medical emergencies, and developmental impairments FINTEPLA was approved by the European Commission in December 2020 based on data from two Phase 3 studies demonstrating it safely and significantly reduced convulsive seizure frequency for Dravet syndrome patients whose seizures were not adequately controlled on t...

Onxeo Obtains Non-dilutive Financing of 5 Million Euros in the Form of State Guaranteed Loans rd quarter of 2022 Regulatory News: Onxeo S.A. (Euronext Growth: ALONX; Nasdaq First North: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, today announces that it has secured a €5 million financing with a group of French banks, in the form of State Guaranteed...

Our NanoNews Digest Sponsors Home > Press > Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia Abstract: Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2b dose-finding clinical study of ARO-ANG3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patient...